info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Procurement Channels for Enasidenib?
501
Article source: Seagull Pharmacy
Dec 23, 2025

Enasidenib is a targeted drug indicated for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation, and its trade name is IDHIFA. Given its specific indications and prescription-only nature, patients and their family members need to understand the legitimate procurement channels, pay attention to medication safety, and learn to identify the authenticity of the drug.

What Are the Procurement Channels for Enasidenib?

Overseas Purchase

Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries or regions where Enasidenib has been approved for marketing.

As drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels as well as professional consultation and guidance.

Precautions for Purchasing Enasidenib

Strictly Follow the Doctor’s Advice

Enasidenib is a specialized targeted drug, and a prescription must be issued by a physician based on the results of genetic testing (IDH2 mutation).

Patients must not self-assess their condition or purchase the drug based on personal experience.

Confirm the Drug Version and Specification

Enasidenib is currently available in two specifications: 50 mg and 100 mg.

Patients need to confirm the required dosage according to the doctor’s advice and check the markings on the tablets (e.g., “ENA50” or “ENA100”).

Understand the Drug Storage Conditions

Enasidenib should be stored at room temperature between 20°C and 25°C, protected from moisture.

Before purchasing, inspect the packaging for integrity, check whether a desiccant is included in the bottle, and ensure the drug is used within its expiration date.

Monitoring During Medication

Before medication initiation and in the early stage of treatment, regular monitoring of blood routine, liver and kidney function, and other indicators is required to prevent serious adverse reactions such as differentiation syndrome and tumor lysis syndrome.

Patients should maintain close communication with their doctors and report any discomfort symptoms promptly.

How to Identify the Authenticity of Enasidenib?

Inspect the Outer Packaging and Label

The packaging of genuine drugs should feature clear printing and complete information, including the drug name, specification, batch number, expiration date, manufacturer (e.g., Bristol Myers Squibb), and import drug registration certificate number.

The bottle should be properly sealed, with a desiccant enclosed.

Verify the Tablet Appearance

The 50 mg tablet is pale yellow to yellow, oval-shaped, engraved with “ENA” on one side and “50” on the other.

The 100 mg tablet is pale yellow to yellow, capsule-shaped, engraved with “ENA” on one side and “100” on the other.

If the tablet’s color, shape, or engraving is blurred or inconsistent with the above descriptions, the authenticity of the drug should be highly suspected.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Enasidenib(Idhifa)
Enasidenib(Idhifa)
Treatment of relapsed or refractory acute myeloid leukemia (AML) in adult...
WeChat Scan
Free Inquiry
Recommended Articles
Adverse Reactions of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a targeted therapy for RET fusion-positive tumors. While delivering therapeutic benefits to patients, it is also associated with potential risks that cannot be ignored.Adverse...
What Are the Precautions for Pralsetinib (Gavreto) Administration?
Pralsetinib (Gavreto) is a new-generation highly selective RET inhibitor, offering a breakthrough treatment option for patients with RET fusion-positive non-small cell lung cancer and thyroid cancer.W...
Dosage and Administration, Recommended Dose of Pralsetinib (Gavreto)
Pralsetinib (Gavreto) is a kinase inhibitor targeting RET gene fusions, and it demonstrates significant value in the treatment of metastatic RET fusion-positive non-small cell lung cancer and thyroid ...
What Are the Indications for Pralsetinib (Gavreto)?
Pralsetinib (Gavreto) is an oral kinase inhibitor primarily indicated for the treatment of specific malignant tumors associated with RET gene alterations. Manufactured by Genentech, this drug first re...
What Are the Indications for Enasidenib?
Enasidenib is an oral isocitrate dehydrogenase-2 (IDH2) inhibitor, which was first approved for marketing in the United States in 2017 for the treatment of specific types of acute myeloid leukemia (AM...
Dosage and Administration, Recommended Dose of Enasidenib
As an isocitrate dehydrogenase-2 (IDH2) inhibitor, Enasidenib offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML). Its unique mechanism of action t...
What are the Precautions for Enasidenib Administration?
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor that offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML).What are the Precautions for ...
Side Effects of Enasidenib
Enasidenib is a targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a specific genetic mutation (IDH2 mutation).Side Effects of EnasidenibCommon Side...
Related Articles
Enasidenib Dosage and Administration, Recommended Dose
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation.Enasideni...
Side Effects of Enasidenib
Enasidenib is a targeted therapeutic agent for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.Side Effects of EnasidenibGastroi...
What are the Precautions for Enasidenib Use?
Enasidenib is an oral targeted therapy drug for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an isocitrate dehydrogenase 2 (IDH2) mutation. It was first approved f...
What are the indications for Enasidenib?
Enasidenib is an oral targeted therapy drug, marketed under the brand name IDHIFA®, which was first approved for marketing in the United States in 2017. It is an isocitrate dehydrogenase-2 (IDH2) inhi...
Purchase Channels for Enasidenib
Enasidenib is a targeted drug for relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations.Purchase Channels for EnasidenibOverseas Purchase(1) Patients may choose to visit hospital pha...
Side Effects of Enasidenib
Enasidenib is a targeted therapy for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a specific genetic mutation (IDH2 mutation).Side Effects of EnasidenibCommon Side...
What are the Precautions for Enasidenib Administration?
Enasidenib is an isocitrate dehydrogenase-2 (IDH2) inhibitor that offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML).What are the Precautions for ...
Dosage and Administration, Recommended Dose of Enasidenib
As an isocitrate dehydrogenase-2 (IDH2) inhibitor, Enasidenib offers a targeted treatment option for patients with relapsed or refractory acute myeloid leukemia (AML). Its unique mechanism of action t...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • haiousales@gmail.com
Welcome to consult
Seagull Pharmacy.,Ltd All rights reserved